Low risk of embryonic and other cancers in PIK3CA-related overgrowth spectrum: Impact on screening recommendations

Clin Genet. 2023 Nov;104(5):554-563. doi: 10.1111/cge.14410. Epub 2023 Aug 14.

Abstract

The PIK3CA-related overgrowth spectrum (PROS) encompasses various conditions caused by mosaic activating PIK3CA variants. PIK3CA somatic variants are also involved in various cancer types. Some generalized overgrowth syndromes are associated with an increased risk of Wilms tumor (WT). In PROS, abdominal ultrasound surveillance has been advocated to detect WT. We aimed to determine the risk of embryonic and other types of tumors in patients with PROS in order to evaluate surveillance relevance. We searched the clinical charts from 267 PROS patients for the diagnosis of cancer, and reviewed the medical literature for the risk of cancer. In our cohort, six patients developed a cancer (2.2%), and Kaplan Meier analyses estimated cumulative probabilities of cancer occurrence at 45 years of age was 5.6% (95% CI = 1.35%-21.8%). The presence of the PIK3CA variant was only confirmed in two out of four tumor samples. In the literature and our cohort, six cases of Wilms tumor/nephrogenic rests (0.12%) and four cases of other cancers have been reported out of 483 proven PIK3CA patients, in particular the p.(His1047Leu/Arg) variant. The risk of WT in PROS being lower than 5%, this is insufficient evidence to recommend routine abdominal imaging. Long-term follow-up studies are needed to evaluate the risk of other cancer types, as well as the relationship with the extent of tissue mosaicism and the presence or not of the variant in the tumor samples.

Trial registration: ClinicalTrials.gov NCT01950975.

Keywords: PIK3CA; PIK3CA-related overgrowth spectrum (PROS); Wilms tumor; cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Class I Phosphatidylinositol 3-Kinases / genetics
  • Early Detection of Cancer
  • Growth Disorders / diagnosis
  • Humans
  • Kidney Neoplasms*
  • Mutation
  • Wilms Tumor* / diagnosis
  • Wilms Tumor* / epidemiology
  • Wilms Tumor* / genetics

Substances

  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human

Associated data

  • ClinicalTrials.gov/NCT01950975